Postoperative complications in women with ovarian cancer stratified by cytoreductive surgery outcome

被引:2
|
作者
Polan, Rosa M. [1 ]
Slota, Jennifer M. [2 ]
Barber, Emma L. [2 ,3 ,4 ]
机构
[1] Wayne State Univ, Karmanos Canc Inst, Div Gynecol Oncol, Detroit, MI 48202 USA
[2] Northwestern Univ, Dept Obstet & Gynecol, Div Gynecol Oncol, Chicago, IL USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Dept Oncol, Chicago, IL USA
[4] Inst Publ Hlth Med, Surg Outcomes & Qual Improvement Ctr, Dept Gynecol, Chicago, IL USA
关键词
cytoreduction; debulking; no gross residual; optimal; ovarian cancer; suboptimal; PRIMARY DEBULKING SURGERY; SURVIVAL; CHEMOTHERAPY; CARCINOMA; DISEASE;
D O I
10.1002/jso.27380
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveTo compare 30-day postoperative complications for patients with advanced ovarian cancer who underwent resection to no gross residual disease versus optimal and suboptimal cytoreduction. MethodsA retrospective cohort study of women drawn from the National Surgical Quality Improvement Program who underwent cytoreductive surgery for advanced ovarian cancer between 2014 and 2019 was performed. Exposure of interest was extent of surgical resection defined as no gross residual disease; residual disease <1 cm (optimal); and residual disease >1 cm (suboptimal). Primary outcome was postoperative complication. Associations were examined with bivariable tests and multivariable logistic regression. ResultsA total of 2248 women underwent cytoreductive surgery; 68.4% (n = 1538) underwent resection to no gross residual disease, 22.4% (n = 504) had an optimal, and 9.2% (n = 206) had a suboptimal cytoreduction. Optimal cytoreduction patients had the highest rates of any postoperative complication (35.5%, p < 0.001). They also had the longest operative times and procedures that were most surgically complex (203 min, 43.6 relative value units, both p < 0.05). However, patients who underwent optimal cytoreduction did not have increased odds of major complications (adjusted odds ratio: 1.20, 95% confidence interval: 0.91-1.58). ConclusionPatients who underwent optimal cytoreduction had more postoperative complications, required the most operating room time, and represented more complex surgeries compared with suboptimal cytoreduction or resection to no gross residual disease.
引用
收藏
页码:891 / 901
页数:11
相关论文
共 50 条
  • [21] Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study
    Ade, Carl J.
    Dockery, Lauren
    Walter, Adam C.
    Benbrook, Doris M.
    Vesely, Sara K.
    Hammond, Stephen T.
    Moore, Kathleen N.
    Holman, Laura L.
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2023, 75 (02): : 662 - 669
  • [22] A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer
    Eng, Oliver S.
    Raoof, Mustafa
    Blakely, Andrew M.
    Yu, Xian
    Lee, Stephen J.
    Han, Ernest S.
    Wakabayashi, Mark T.
    Yuh, Bertram
    Lee, Byrne
    Dellinger, Thanh H.
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (01) : 121 - 126
  • [23] Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data
    Abdallah, Reem
    Chon, Hye Sook
    Zgheib, Nadim Bou
    Marchion, Douglas C.
    Wenham, Robert M.
    Lancaster, Johnathan M.
    Gonzalez-Bosquet, Jesus
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (06) : 1000 - 1009
  • [24] The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer
    Angeles, Martina Aida
    Hernandez, Alicia
    Perez-Benavente, Asuncion
    Cabarrou, Bastien
    Spagnolo, Emanuela
    Rychlik, Agnieszka
    Daboussi, Amel
    Migliorelli, Federico
    Betrian, Sarah
    Ferron, Gwenael
    Gil-Moreno, Antonio
    Guyonj, Frederic
    Martinez, Alejandra
    GYNECOLOGIC ONCOLOGY, 2022, 166 (01) : 8 - 17
  • [25] Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement
    Harrison, R.
    Zighelboim, I
    Cloven, N. G.
    Marcus, J. Z.
    Coleman, R. L.
    Karam, A.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 448 - 452
  • [26] Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles
    Tseng, Jill H.
    Bristow, Robert E.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (01) : 5 - 7
  • [27] Postoperative Complications of Upfront Ovarian Cancer Surgery and Their Effects on Chemotherapy Delay
    Heikkinen, Julia
    Karkkainen, Henna
    Eloranta, Marja-Liisa
    Anttila, Maarit
    CURRENT ONCOLOGY, 2024, 31 (09) : 5630 - 5642
  • [28] Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
    Bristow, Robert E.
    Puri, Isha
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (01) : 265 - 274
  • [29] Splenectomy during Secondary Cytoreductive Surgery for Epithelial Ovarian Cancer
    Hanprasertpong, Jitti
    Ohishi, Rie
    Iwasa, Norihiro
    Nagao, Shoji
    Okamoto, Kojun
    Fujiwara, Keiichi
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (02) : 413 - 416
  • [30] Cytoreductive surgery for ovarian cancer
    Kecmanovic, DM
    Pavlov, MJ
    Kovacevic, PA
    Ceranic, MS
    Stamenkovic, AB
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (04): : 315 - 320